Barclays Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective hoisted by Barclays from $266.00 to $300.00 in a report issued on Thursday,Benzinga reports. Barclays currently has an equal weight rating on the medical instruments supplier’s stock.

Other equities analysts have also recently issued research reports about the company. Citigroup reiterated a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Raymond James Financial restated an “outperform” rating and set a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. The Goldman Sachs Group began coverage on shares of Insulet in a research report on Friday, May 30th. They set a “buy” rating and a $380.00 price objective for the company. Finally, Wells Fargo & Company raised their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $332.71.

Insulet Trading Down 1.5%

Insulet stock opened at $327.85 on Thursday. Insulet has a 52 week low of $180.31 and a 52 week high of $334.18. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The stock has a market capitalization of $23.08 billion, a P/E ratio of 99.65, a PEG ratio of 2.79 and a beta of 1.35. The stock has a 50-day simple moving average of $300.42 and a 200 day simple moving average of $285.54.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same quarter last year, the company posted $0.55 earnings per share. Insulet’s quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts expect that Insulet will post 3.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Insulet by 0.5% during the second quarter. Vanguard Group Inc. now owns 8,708,355 shares of the medical instruments supplier’s stock worth $2,735,991,000 after purchasing an additional 39,403 shares during the period. Geode Capital Management LLC increased its holdings in shares of Insulet by 3.1% during the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock worth $603,211,000 after purchasing an additional 58,309 shares during the period. American Century Companies Inc. increased its holdings in shares of Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after purchasing an additional 297,734 shares during the period. Groupama Asset Managment increased its holdings in shares of Insulet by 0.4% during the first quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier’s stock worth $276,728,000 after purchasing an additional 3,759 shares during the period. Finally, Norges Bank bought a new position in shares of Insulet during the second quarter worth approximately $324,689,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.